Proliferative Diabetic Retinopathy Clinical Trial
Official title:
Pilot Study OCT of Retinal Blood Flow in Proliferative Diabetic Retinopathy Before and After Panretinal Photocoagulation
The purpose of this study is to evaluate the effectiveness of investigational Doppler Optical Coherence Tomography (OCT) and OCT angiography in the management of proliferative diabetic retinopathy (PDR - a leading cause of blindness in diabetic patients) before and after treatment. Angiography is the mapping of the blood vessels, and Doppler detects blood flow. PDR is due to poor oxygen circulation in smaller blood vessels in the back of the eye (retina), and is observed in 80% of people who have had diabetes for more than 10 years. This study will look at how blood flow to the eye is affected before and after treatment.
Diabetic retinopathy (DR) refers to changes in the blood vessels of the retina associated
with long-term diabetes mellitus. These changes can be found in patients both with Type I and
II diabetes. DR is a leading cause of blindness in the United States. It is categorized as
either non-proliferative (NPDR) or proliferative (PDR). In the PDR progress, the lack of
oxygen in the retina causes fragile, new blood vessels to grow along the retina and in the
clear, gel-like vitreous humour. Without timely treatment, the new vessels can bleed, cloud
vision, and destroy the retina. So, the PDR is classified as either the existence of retinal
neovascularization or vitreous or pre-retinal hemorrhage. PDR is typically treated with a
laser, known as panretinal photocoagulation (PRP), which will create 1,600-2,000 burns in the
retina to reduce the retinal oxygen demand, and then reduce the possibility of ischemia, or
with an injection of an anti-vascular endothelial growth factor (anti-VEGF) drug into the
vitreous, which always needs multiple injections. In cases of severe bleeding, a vitrectomy
may be performed under local anesthesia. However, an eye patch and medicated eye drops are
always needed after the operation to protect against infection and the outcomes are not
always as good as expected.
PDR is currently diagnosed by a comprehensive eye exam including a visual acuity test,
ophthalmoscopy or fundus photography, fluorescein angiography (FA) and optical coherence
tomography (OCT). If the PDR is thought to require treatment, the subsequent assessment of
disease severity and treatment planning utilizes FA. FA requires the injection of sodium
fluorescein into the systemic circulation. However, 1 in 3 people have adverse reactions to
sodium fluorescein, which can include nausea, vomiting, hives, and acute hypotension. Severe
reactions such as anaphylaxis and related anaphylactoid reactions, causing cardiac arrest and
sudden death due to anaphylactic shock, have also been reported. Finally, because the risks
of sodium fluorescein to a developing fetus are unknown, its use in pregnant women is
contraindicated. Replacing FA with a less invasive and better tolerated method would reduce
the risk in the patient population. One option is OCT angiography.
Optical coherence tomography is an imaging technology that can perform non-contact
cross-sectional imaging of tissue structure in real time. It has a number of features that
make it attractive as a diagnostic imaging modality: 1) It has micron-level resolution, which
is not possible with any other non-contact technique; 2) No potentially allergenic dyes or
contrast agents are required; 3) OCT images are generated in electronic form, which
facilitates the use of digital image processing techniques to extract quantitative parameters
regarding the imaged tissue anatomy. For these reasons, structural OCT is already routinely
used to assess the early stage of DR (NPDR) by imaging the areas of macular edema and
response to treatment. Novel functional OCT including Doppler OCT and OCT angiography may
allow an assessment of retinal blood flow and alleviate the need for the more invasive FA
test. Thus, if the diagnostic data provided by functional OCT are at least equivalent or
superior to those achieved by FA, patients and healthcare providers could realize a
substantial benefit in utilizing this technology in the management of PDR and the evaluation
of PRP.
Therefore, we propose a pilot study to evaluate the feasibility of Doppler OCT to measure
total retinal blood flow to assess global retinal ischemia after PRP treatment and OCT
angiography of the retina to assess proliferative changes in the management of PDR subjects
in comparison to standard FA. Functional OCT data (Doppler OCT and OCT angiography) are
acquired using the Swept Source-OCT (SS-OCT) with a depth resolution of 5 microns and an
ultrafast scan rate of 100 kHz which allows us to obtain detailed 3D OCT images. OCT
angiography performs noninvasive microcirculation measurement and visualization which are not
options on commercially available OCT systems. Though not FDA-approved, the SS-OCT prototype
satisfies the American national standards for laser safety (ANSI) safety requirement. The
power level is low enough to be classified as a non-significant risk device.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01921192 -
Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy
|
Phase 4 | |
Recruiting |
NCT01044875 -
Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy
|
N/A | |
Active, not recruiting |
NCT00993525 -
Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
|
Phase 1/Phase 2 | |
Completed |
NCT01307072 -
Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT01758757 -
Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy
|
N/A | |
Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
Completed |
NCT05408416 -
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
|
N/A | |
Completed |
NCT05414149 -
Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy
|
N/A | |
Not yet recruiting |
NCT04464694 -
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
|
Phase 4 | |
Not yet recruiting |
NCT03633266 -
Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy
|
N/A | |
Completed |
NCT03490318 -
Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
|
||
Completed |
NCT01627977 -
Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy
|
Phase 3 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Terminated |
NCT00563043 -
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
|
Phase 4 | |
Completed |
NCT00682240 -
Morphological and Functional Retinal Changes Following Retinal Photocoagulation
|
Phase 4 | |
Terminated |
NCT00563628 -
Changes in Macular Thickness After Patterns Scan Laser
|
Phase 4 | |
Completed |
NCT00446381 -
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
|
N/A | |
Completed |
NCT02879422 -
Genetic Markers and Proliferative Diabetic Retinopathy
|
N/A | |
Enrolling by invitation |
NCT02911311 -
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
|
N/A | |
Recruiting |
NCT05514925 -
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
|
Phase 4 |